Form 4 for CLB Core Laboratories Inc. /DE/
Accepted 2026-01-05 00:00:00 ET · period of report 2025-12-31 · accession 0001193125-26-002257 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-05 | 2025-12-31 | CLB | Tattoli Mark Damian | SVP, Gen Counsel, Sec | M - OptEx | $0.00 | +25.0K | 41.7K | +149% | $0 |
| D | 2026-01-05 | 2025-12-31 | CLB | Tattoli Mark Damian | SVP, Gen Counsel, Sec | F - Tax | $16.03 | -14.3K | 27.4K | -34% | -$229.4K |
| D | 2026-01-05 | 2025-12-31 | CLB | Tattoli Mark Damian | SVP, Gen Counsel, Sec | M - OptEx | $0.00 | -25.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | M | A | 24,952 | $0.00 | 41,670.62 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-31 | F | D | 14,310 | $16.03 | 27,360.62 | D | — | — | |
| 3 | Derivative | Performance Shares | 2025-12-31 | M | D | 24,952 | $0.00 | 0 | D | $0.00 · — to — | 24,952 Common Stock | (F1) These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025. |